BridgeMD
New treatment option for Head and Neck Tumors
Official title Multiparametric Imaging-based Intraoperative Navigation for Guidance of Surgical Resection and Postoperative Radiotherapy in Patients With Head-and-neck Tumors
ClinicalTrials.gov ID: NCT05671458
What this study is testing
- What it's testing
- The overarching goal of the NAVIGATORR trial is the improvement of local tumor control in head-and-neck cancer (HNC) by increasing the precision of surgical resection and individualization of radiotherapy. Squamous cell carcinomas (SCC) together with salivary gland carcinomas (adenoid cysytic Carcinoma (ACC), mucoepidermoid Carcinoma (MEC), adenocarcinoma (AC)) represent the most common entities in German head and neck oncology.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Diagnosis of a malignancy (squamous cell carcinoma (SCC), adenocarcinoma (AC), mucoepidermoid carcinoma (MEC), adenoidcystic carcinoma (ACC)) of the...
- Indication of surgical tumor resection according to multidisciplinary tumor conference
- Probably indication for postoperative radiotherapy (e.g. T3/4 tumor)
- Medical operability and written informed consent of the patient to undergo surgical resection (as indicated clinically)
- Patient age ≥ 18 years
You likely can't join if
- Contraindications against radiotherapy, especially pregnant or lactating women
- Refusal of the patient to take part in the study
- Participation in another competing clinical study or observation period of competing trials
See the full eligibility criteria
- Diagnosis of a malignancy (squamous cell carcinoma (SCC), adenocarcinoma (AC), mucoepidermoid carcinoma (MEC), adenoidcystic carcinoma (ACC)) of the midface, upper jaw and skull-base (e.g. based on imaging-studies...
- Indication of surgical tumor resection according to multidisciplinary tumor conference
- Probably indication for postoperative radiotherapy (e.g. T3/4 tumor)
- Medical operability and written informed consent of the patient to undergo surgical resection (as indicated clinically)
- Patient age ≥ 18 years
- Karnofsky performance index ≥ 60%
- For women with childbearing potential: adequate contraception
- Ability of subject to understand character and individual consequences of the trial
- Written informed consent to participate in this trial
- Contraindications against radiotherapy, especially pregnant or lactating women
- Refusal of the patient to take part in the study
- Participation in another competing clinical study or observation period of competing trials
The study team makes the final eligibility decision.
Where it's taking place
- Heidelberg, Germany
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Heidelberg, Germany. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.